Business Wire

DVB Bank’s Aviation Investment and Asset Management Business to Be Acquired by SVPGlobal and EnTrust Global

11.3.2021 15:00:00 EET | Business Wire | Press release

Share

The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced that they have entered into a definitive agreement to acquire the Aviation Investment and Asset Management business (the “Business”) from DVB Bank Group. The transaction is expected to close during the first half of 2021.

The Business, one of the top 10 aviation service companies globally, will be acquired through a newly incorporated UK company, Deucalion Aviation Limited (“Deucalion” or the “Company”). Today, the Business is a global aviation management platform that provides comprehensive turnkey solutions for financial investors looking to deploy capital in aircraft assets, through origination, structuring, execution, fund management and a full-fledged range of servicing activities, including aircraft remarketing, technical management, lease management and consultancy. The 45-strong team manages approximately 160 aircraft on lease to more than 80 airlines globally, representing approximately $5 billion in total asset value.

EnTrust and SVPGlobal’s investment is expected to provide the support required by the existing management team to build on its international growth strategy and explore complementary opportunities arising from the current aviation industry dislocation.

Deucalion, which will be led jointly by Jon Skirrow and Stephan Sayre, will be acquired through a joint venture formed between EnTrust and SVPGlobal, utilising the two firms’ complementary expertise. Senior members of the EnTrust Blue Sky Aviation and SVPGlobal teams have worked together on various transactions over the past 15 years.

Jon Skirrow said: “We are delighted to be partnering with EnTrust and SVPGlobal, following many successful years with DVB Bank Group. This new investment will support us in capitalizing on our strong growth trajectory, and we look forward to continuing to provide our world-leading services to our clients as we embark on the next stage of our development.”

Stephan Sayre added: “EnTrust and SVPGlobal, who share our vision of the opportunities in this sector today and in the long term, enable us not only to reinforce our commitment to providing best-in-class service for our clients, but also to significantly strengthen our offering of a broad array of innovative financing solutions to airline and leasing clients globally in the current environment.”

Victor Khosla, Founder & CIO of SVPGlobal, said: “This is an innovative platform with world class aviation expertise and an excellent track record in managing complex, large and unique projects across diversified asset types and structures over the last 17 years. Our investment as part of this joint venture with EnTrust is a testament to the sizeable market opportunity set we see ahead for the business.”

John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “As we continue to build a multi-faceted, relative value investment platform in the aviation industry, this acquisition enhances EnTrust’s Blue Sky Aviation strategy with the full service capabilities critical to providing a wide offering of solutions to constituents within the market. We look forward to the opportunity to partner with SVPGlobal and the talented DVB management team, with whom our team has a long-standing relationship.”

About DVB

DVB Bank SE is a financial services provider specialising in international transport finance. With 329 employees and offices worldwide, the Bank manages a loan portfolio worth €3.9 billion. As an affiliate of DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, DVB is part of Germany's second-largest banking group. Please visit our website www.dvbbank.com for additional information.

About EnTrust Global

EnTrust Global is a leading alternative asset management firm with approximately $19 billion in total assets*. Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 47 countries and has approximately $10 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 11 offices worldwide and is headquartered in New York and London.

*As of September 30, 2020. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.

About Strategic Value Partners

SVPGlobal is a global investment firm with approximately $11 billion in assets under management. The firm, established by Victor Khosla in 2001, has 127 employees, including 49 investment professionals, across its main offices in Greenwich (CT), London and Tokyo. Learn more at www.svpglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DVB
Stephan Sayre
Stephan.Sayre@dvbbank.com
+44 207 2564 344

Jon Skirrow
Jon.Skirrow@dvbbank.com
+44 207 2564 430

EnTrust Global
Hiltzik Strategies
Meghan Kilkenny, Chris Cunningham
EnTrust@hstrategies.com
+1 (212) 792-9338

SVPGlobal Europe
Greenbrook Communications
James Madsen, Mikaela Murekian, Fanni Bodri
svp@greenbrookpr.com
+44 20 7952 2000

SVPGlobal – North America
Kekst CNC
Todd Fogarty, Richard Goldman
SVPGlobal@kekstcnc.com
+1 (212) 521-4800

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye